Irinotecan hydrochloride
Based on 88 publication(s) in Google Scholar
Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.89%
- CAS. Nr.: 100286-90-6
- Formel: C33H39ClN4O6
- Molecular Weight:623.14
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-90006
5-FluorouracilThymidylate Synthase Inhibitor -
HY-13704
SN-38Topoisomerase I Inhibitor -
HY-13768A
Topotecan hydrochlorideTopoisomerase I Inhibitor -
HY-16562
IrinotecanTopoisomerase I Inhibitor -
HY-17371
OxaliplatinDNA Synthesis Inhibitor -
HY-17394
CisplatinDNA Alkylator -
HY-16560
CamptothecinTopo I inhibitor -
HY-B0015
PaclitaxelAntitumor Agent -
HY-10162
OlaparibPARP Inhibitor -
HY-13664
Folinic acid calciumBiological Folic Acid -
HY-13629
EtoposideTopoisomerase II Inhibitor -
HY-17026
GemcitabineDNA Synthesis Inhibitor
Publications Citing Use of MedChemExpress (MCE) Irinotecan hydrochloride
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2021 May 28;6(1):188. [Abstract]
- Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
- Cancer Cell. 2025 Sep 25:S1535-6108(25)00393-9. [Abstract]
- Cancer Cell. 2025 Jul 14;43(7):1296-1312.e7. [Abstract]
- Cell. 2022 Sep 1;185(18):3356-3374.e22. [Abstract]
- Mol Cancer. 2024 Apr 4;23(1):70. [Abstract]
- Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
- Adv Mater. 2026 Mar 15:e22617. [Abstract]
- Nat Commun. 2026 May 28.
- Cell Discov. 2022 Sep 14;8(1):92. [Abstract]
- Redox Biol. 2024 Jul:73:103207. [Abstract]
- Theranostics. 2019 May 31;9(13):3732-3753. [Abstract]
- Acta Pharm Sin B. 2024 Apr;14(4):1677-1692. [Abstract]
- Adv Sci (Weinh). 2026 Jul 13:e76478.
- Adv Sci (Weinh). 2025 Jul;12(27):e2500271. [Abstract]
- Adv Sci (Weinh). 2025 Mar;12(12):e2408845. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Cell Rep Med. 2024 Mar 19;5(3):101468. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- Biomaterials. 2022 Oct:289:121800. [Abstract]
- Cell Death Dis. 2025 Apr 5;16(1):253. [Abstract]
- Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
- Cell Death Dis. 2025 Jan 18;16(1):28. [Abstract]
- Cell Death Dis. 2024 Jun 15;15(6):417. [Abstract]
- Pharmacol Res. 2021 Jan:163:105232. [Abstract]
- Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]
- Cancer Lett. 2026 Jul 10:658:218725.
- Cancer Lett. 2026 Jan 28:638:218156. [Abstract]
- Cancer Lett. 2023 Feb 1:554:216028. [Abstract]
- EBioMedicine. 2023 Jun:92:104594. [Abstract]
- Clin Cancer Res. 2023 Nov 14;29(22):4644-4659. [Abstract]
- Genome Med. 2016 Oct 31;8(1):116. [Abstract]
- Acta Biomater. 2025 Sep 15:204:582-595. [Abstract]
- NPJ Precis Oncol. 2025 Jul 1;9(1):207. [Abstract]
- Oncogene. 2026 Jun 15. [Abstract]
- Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]
- Apoptosis. 2019 Apr;24(3-4):312-325. [Abstract]
- Apoptosis. 2016 Feb;21(2):130-42. [Abstract]
- Mol Ther Oncol. 2025 Nov 22;33(4):201098. [Abstract]
- Cell Rep. 2026 Jul 28;45(7):117686.
- Front Immunol. 2018 Jan 5:8:1919. [Abstract]
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- PLoS Biol. 2022 Feb 24;20(2):e3001517. [Abstract]
- Mol Cancer Ther. 2021 Dec;20(12):2483-2494. [Abstract]
- Cell Biosci. 2023 Nov 25;13(1):215. [Abstract]
- Biochem Pharmacol. 2023 Oct:216:115752. [Abstract]
- Precis Clin Med. 2026 Mar 14;9(2):pbag009. [Abstract]
- Life Sci. 2026 Mar 15:389:124236. [Abstract]
- Life Sci. 2019 Aug 15:231:116529. [Abstract]
- Cells. 2026 Feb 28;15(5):430. [Abstract]
- Int J Pharm. 2020 Jun 30:584:119337. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Mol Cancer Res. 2020 Mar;18(3):414-423. [Abstract]
- Eur J Pharmacol. 2023 Jun 15:949:175718. [Abstract]
- Food Hydrocoll Health. 2025 Jun.
- Lung Cancer. 2023 Apr:178:237-246. [Abstract]
- J Mol Med (Berl). 2026 Apr 23;104(1):68. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Dec;1870(8):167471. [Abstract]
- Eur J Pharm Biopharm. 2022 Feb:171:39-49. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Sci Rep. 2024 Nov 26;14(1):29265. [Abstract]
- PLoS Pathog. 2020 Mar 24;16(3):e1008429. [Abstract]
- Cancers (Basel). 2023 Sep 6;15(18):4442. [Abstract]
- Mol Oncol. 2026 Jun 5. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- J Pharm Pharmacol. 2023 Apr 7;75(4):523-532. [Abstract]
- Mol Biol Cell. 2023 May 1;34(5):ar47. [Abstract]
- Gene. 2019 Mar 10:688:1-6. [Abstract]
- BMC Med Genomics. 2025 Oct 30;18(1):172. [Abstract]
- Biomed Pharmacother. 2026 Sep:202:119803.
- Complutense University of Madrid. 2026.
- bioRxiv. 2026 Jul 8.
- University of North Carolina at Chapel Hill. 2026.
- bioRxiv. 2026 May 23:2026.05.20.726695. [Abstract]
- SSRN. 2026 Jan 26.
- Res Sq. 2026 Jan 9.
- Res Sq. 2025 Nov 19:rs.3.rs-7682325. [Abstract]
- bioRxiv. 2025 Sep 26:2025.09.24.677357. [Abstract]
- bioRxiv. 2025 Sep 21.
- bioRxiv. 2025 Sep 17.
- bioRxiv. 2025 Jul 12:2025.07.08.663754. [Abstract]
- Biomed Pharmacother. 2023 Jul:163:114751. [Abstract]
- Heliyon. 2023 Apr 27;9(5):e15805. [Abstract]
- Ruperto Carola University Heidelberg. 2022 Mcr 16.
- Patent. US20210009719A1.
- Biomed Pharmacother. 2020 Aug:128:110262. [Abstract]
- bioRxiv. 2019 Dec.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
IHC
-
In Vivo Efficacy Study
-
Cell Imaging/Staining
Alle Topoisomerase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
Topoisomerase I |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Astrocyte | IC50 |
>10 μM
Compound: Irinotecan HCl
|
Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
|
[PMID: 26355532] |
| HepG2 | IC50 |
0.95 μM
Compound: Irinotecan hydrochloride
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 32081629] |
| U-373MG ATCC | IC50 |
3.6 μM
Compound: CPT-11, irinotecan
|
Cytotoxicity against human U373MG cells expressing human intestinal carboxylesterase after 4 days in drug free medium by coulter counter
Cytotoxicity against human U373MG cells expressing human intestinal carboxylesterase after 4 days in drug free medium by coulter counter
|
[PMID: 21733699] |
In Vitro
Irinotecan hydrochloride is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 100286-90-6
-
Appearance Solid
-
Molecular Weight 623.14
-
Formel C33H39ClN4O6
-
Color White to yellow
-
SMILES
O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.[H]Cl
-
Synonyms
(+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (88)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS. [Abstract]2021 May 28;6(1):188. PMID: 34045438
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 May 28;6(1):188. [Abstract]
Irinotecan (10 μM; 0–4 days). Cystine promoted colon cancer resistance to oxaliplatin and irinotecan (CPT-11) in vitro.
-
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606 -
Cancer Cell
Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches. [Abstract]2025 Sep 25:S1535-6108(25)00393-9. PMID: 41005303 -
Cancer Cell
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. [Abstract]2025 Jul 14;43(7):1296-1312.e7. PMID: 40513578 -
Cell
2022 Sep 1;185(18):3356-3374.e22. PMID: 36055199 -
Mol Cancer
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation. [Abstract]2024 Apr 4;23(1):70. PMID: 38576002 -
Gastroenterology
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]2021 Nov;161(5):1601-1614.e23. PMID: 34303658 -
Adv Mater
Efficacy and Safety Assessment of 5-Fluorouracil, Irinotecan and Oxaliplatin-Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy. [Abstract]2026 Mar 15:e22617. PMID: 41834342 -
-
Cell Discov
Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas. [Abstract]2022 Sep 14;8(1):92. PMID: 36104333 -
Redox Biol
Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. [Abstract]2024 Jul:73:103207. PMID: 38805974 -
Theranostics
A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment. [Abstract]2019 May 31;9(13):3732-3753. PMID: 31281510 -
Acta Pharm Sin B
Eubacterium coprostanoligenes alleviates chemotherapy-induced intestinal mucositis by enhancing intestinal mucus barrier. [Abstract]2024 Apr;14(4):1677-1692. PMID: 38572095
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692. [Abstract]
Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Tumor volume in the control, CPT/5FU and E. copr groups were recorded daily.
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 Apr;14(4):1677-1692. [Abstract]
Irinotecan (25 mg/kg/day) were administered intraperitoneally from Day 0 to Day 4. Expression of PCNA was measured by IHC and quantified by ImageJ in the tumor sections. Scale bar: 100 mm.
-
-
Adv Sci (Weinh)
PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti-TIGIT Therapy in Microsatellite-Stable Colorectal Cancer. [Abstract]2025 Jul;12(27):e2500271. PMID: 40344511 -
Adv Sci (Weinh)
2025 Mar;12(12):e2408845. PMID: 39888307 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Cell Rep Med
Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. [Abstract]2024 Mar 19;5(3):101468. PMID: 38508144 -
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
Biomaterials
2022 Oct:289:121800. PMID: 36166893 -
Cell Death Dis
Mitochondrial, metabolic and bioenergetic adaptations drive plasticity of colorectal cancer cells and shape their chemosensitivity. [Abstract]2025 Apr 5;16(1):253. PMID: 40185729 -
Cell Death Dis
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]2025 Mar 12;16(1):170. PMID: 40075071 -
Cell Death Dis
Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]2025 Jan 18;16(1):28. PMID: 39827156 -
Cell Death Dis
Golgi dispersal in cancer stem cells promotes chemoresistance of colorectal cancer via the Golgi stress response. [Abstract]2024 Jun 15;15(6):417. PMID: 38879509 -
Pharmacol Res
Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism. [Abstract]2021 Jan:163:105232. PMID: 33027716 -
Cell Death Dis
Knockdown of cytokeratin 8 overcomes chemoresistance of chordoma cells by aggravating endoplasmic reticulum stress through PERK/eIF2α arm of unfolded protein response and blocking autophagy. [Abstract]2019 Nov 25;10(12):887. PMID: 31767864 -
-
Cancer Lett
2026 Jan 28:638:218156. PMID: 41265630 -
Cancer Lett
High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]2023 Feb 1:554:216028. PMID: 36462556 -
EBioMedicine
A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation. [Abstract]2023 Jun:92:104594. PMID: 37167784 -
Clin Cancer Res
Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair. [Abstract]2023 Nov 14;29(22):4644-4659. PMID: 37725585 -
Genome Med
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. [Abstract]2016 Oct 31;8(1):116. PMID: 27799065 -
Acta Biomater
MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway. [Abstract]2025 Sep 15:204:582-595. PMID: 40812610 -
NPJ Precis Oncol
Consensus artificial intelligence-driven prognostic signature for predicting the prognosis of hepatocellular carcinoma: a multi-center and large-scale study. [Abstract]2025 Jul 1;9(1):207. PMID: 40595395 -
Oncogene
Amphiregulin drives EGFR-dependent genome stability in colorectal cancer and represents a targetable vulnerability. [Abstract]2026 Jun 15. PMID: 42298179 -
Oncogene
CBX3 promotes multidrug resistance by suppressing ferroptosis in colorectal carcinoma via the CUL3/NRF2/GPX2 axis. [Abstract]2025 Jun;44(22):1678-1693. PMID: 40089640
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]
Analysis of drug sensitivity in various SW480 and HCT116 cell lines after 48 h of treatment with with Irinotecan (1 μmol/L).
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]
Irinotecan (1 μmol/L, 48 h). Western blotting assays on caspase-3 and cleaved caspase-3 in SW480-Con/CBX3 cells following chemotherapy.
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]
Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Immunohistochemical staining of tumor tissues with antibodies against Ki67, NRF2, and GPX2 (low-power view 100×, high-power view 400×, scale bar = 50 μm).
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]
Irinotecan (50 mg/kg, twice a week, administered intraperitoneally). Tumors were measured every two days, and the tumor volumes were calculated. The tumors were excised and weighed 34 days after injection, and representative images of tumors were displayed (bar = 10 mm).
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2025 Jun;44(22):1678-1693. [Abstract]
SW480-Con/CBX3 cells were treated with Irinotecan (1 μmol/L) for 8 h and stained with C11 BODIPY (oxidized lipid was stained green) and then detected by both flow cytometry and confocal microscopy. ERTracker Blue-White was used to detect the location of lipid oxidation by confocal microscopy (high-power view 400×, scale bar = 50 μm) (N = 3).
-
Apoptosis
Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. [Abstract]2019 Apr;24(3-4):312-325. PMID: 30710195 -
Apoptosis
Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. [Abstract]2016 Feb;21(2):130-42. PMID: 26531131
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: Apoptosis. 2016 Feb;21(2):130-42. [Abstract]
(a) CPT-11 induces cell cycle arrest and apoptosis in RAW 264.7macrophages. a.Western blot analysis of cleaved caspase-3 and PARP levels. (b) CPT-11 induced cell cycle arrest and apoptosis in mouse peritoneal macrophages. Western blot analysis of cleaved caspase-3 and PARP levels in peritoneal macrophages isolated from vehicleand CPT-11-administered mice. (c) Caspase-3 inhibitor z-DEVD-fmk (ZD) attenuates CPT-11-induced loss of GATA6+ peritoneal macrophages in mice. Western blot analy
-
Mol Ther Oncol
A KRASG12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [Abstract]2025 Nov 22;33(4):201098. PMID: 41438133 -
-
Front Immunol
Prolonged Deleterious Influences of Chemotherapeutic Agent CPT-11 on Resident Peritoneal Macrophages and B1 Cells. [Abstract]2018 Jan 5:8:1919. PMID: 29354128 -
-
PLoS Biol
2022 Feb 24;20(2):e3001517. PMID: 35202387 -
Mol Cancer Ther
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. [Abstract]2021 Dec;20(12):2483-2494. PMID: 34711645 -
Cell Biosci
2023 Nov 25;13(1):215. PMID: 38007480 -
Biochem Pharmacol
Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice. [Abstract]2023 Oct:216:115752. PMID: 37634598 -
Precis Clin Med
Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. [Abstract]2026 Mar 14;9(2):pbag009. PMID: 41978696 -
Life Sci
A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]2026 Mar 15:389:124236. PMID: 41611204 -
Life Sci
The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice. [Abstract]2019 Aug 15:231:116529. PMID: 31173781 -
Cells
Machine Learning-Driven Multi-Omics Analysis Identifies CHP2 as a Key PANoptosis-Related Dual-Function Biomarker in Colorectal Cancer. [Abstract]2026 Feb 28;15(5):430. PMID: 41827864 -
Int J Pharm
Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel. [Abstract]2020 Jun 30:584:119337. PMID: 32371002 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Mol Cancer Res
2020 Mar;18(3):414-423. PMID: 31932471 -
Eur J Pharmacol
Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer. [Abstract]2023 Jun 15:949:175718. PMID: 37054937 -
-
Lung Cancer
TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. [Abstract]2023 Apr:178:237-246. PMID: 36907051 -
J Mol Med (Berl)
The role and mechanism of TNFRSF21 in promoting necroptosis of vascular endothelial cells and inducing vascular leakage in sepsis. [Abstract]2026 Apr 23;104(1):68. PMID: 42020785 -
Biochim Biophys Acta Mol Basis Dis
Hypoxia-driven heterogeneous expression of α5 integrin in glioblastoma stem cells is linked to HIF-2α. [Abstract]2024 Dec;1870(8):167471. PMID: 39154793 -
Eur J Pharm Biopharm
Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation. [Abstract]2022 Feb:171:39-49. PMID: 34998911 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Sci Rep
EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy. [Abstract]2024 Nov 26;14(1):29265. PMID: 39587206 -
PLoS Pathog
BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses. [Abstract]2020 Mar 24;16(3):e1008429. PMID: 32208449 -
Cancers (Basel)
In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments. [Abstract]2023 Sep 6;15(18):4442. PMID: 37760412 -
Mol Oncol
Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]2026 Jun 5. PMID: 42246237 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
J Pharm Pharmacol
Indolocarbazole alkaloid Loonamycin A inhibits triple-negative breast cancer cell stemness and Notch signalling. [Abstract]2023 Apr 7;75(4):523-532. PMID: 36861187
Irinotecan hydrochloride purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2023 Apr 7;75(4):523-532. [Abstract]
Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.
-
Mol Biol Cell
Mitotic DNA damage promotes chromokinesin-mediated missegregation of polar chromosomes in cancer cells. [Abstract]2023 May 1;34(5):ar47. PMID: 36989031 -
Gene
2019 Mar 10:688:1-6. PMID: 30415007 -
BMC Med Genomics
The role of TEAD4 gene in the Hippo signaling pathway in triple-negative breast cancer and targeted therapy strategies. [Abstract]2025 Oct 30;18(1):172. PMID: 41168787 -
-
-
-
-
bioRxiv
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence. [Abstract]2026 May 23:2026.05.20.726695. PMID: 42239384 -
-
-
Res Sq
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax. [Abstract]2025 Nov 19:rs.3.rs-7682325. PMID: 41333384 -
bioRxiv
CK2 inhibitor CX-4945 targets EWS-FLI1 protein abundance and shows anti-tumor activity in metastatic mouse models of Ewing Sarcoma. [Abstract]2025 Sep 26:2025.09.24.677357. PMID: 41040216 -
-
-
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312 -
Biomed Pharmacother
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]2023 Jul:163:114751. PMID: 37105073 -
Heliyon
The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway. [Abstract]2023 Apr 27;9(5):e15805. PMID: 37251857 -
-
-
Biomed Pharmacother
Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. [Abstract]2020 Aug:128:110262. PMID: 32447214 -
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 125 mg/mL (200.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 3.33 mg/mL (5.34 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 6 mg/mL (9.63 mM); Clear solution
This protocol yields a clear solution of ≥ 6 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (60.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 6 mg/mL (9.63 mM); Clear solution
This protocol yields a clear solution of ≥ 6 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (60.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26. [Content Brief]
[2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30. [Content Brief]
[3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.6048 mL | 8.0239 mL | 16.0478 mL | 40.1194 mL |
| 5 mM | 0.3210 mL | 1.6048 mL | 3.2096 mL | 8.0239 mL | |
| DMSO | 10 mM | 0.1605 mL | 0.8024 mL | 1.6048 mL | 4.0119 mL |
| 15 mM | 0.1070 mL | 0.5349 mL | 1.0699 mL | 2.6746 mL | |
| 20 mM | 0.0802 mL | 0.4012 mL | 0.8024 mL | 2.0060 mL | |
| 25 mM | 0.0642 mL | 0.3210 mL | 0.6419 mL | 1.6048 mL | |
| 30 mM | 0.0535 mL | 0.2675 mL | 0.5349 mL | 1.3373 mL | |
| 40 mM | 0.0401 mL | 0.2006 mL | 0.4012 mL | 1.0030 mL | |
| 50 mM | 0.0321 mL | 0.1605 mL | 0.3210 mL | 0.8024 mL | |
| 60 mM | 0.0267 mL | 0.1337 mL | 0.2675 mL | 0.6687 mL | |
| 80 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.5015 mL | |
| 100 mM | 0.0160 mL | 0.0802 mL | 0.1605 mL | 0.4012 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Irinotecan hydrochloride Related Classifications
HY-16562A Related Classifications
Powered by Bioz